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Abstract
Background: Although increasing donor age adversely affects survival after liver transplantation, livers
have been used from selected deceased donors older than 70 years. Although there are reports of
excellent short-term results, long-term results are unknown. Our experience was reviewed with septua-
genarian and octogenarian deceased donors to determine long-term outcomes.
Methods: All primary deceased donor liver transplants performed at our institution between July 1998 and
December 2010were reviewed. Recipients of livers procured after circulatory arrest, split and reduced-size
livers and multiple organ transplants were excluded from the study. Patient and graft survival were
calculated using the Kaplan–Meier method, and survival comparisons were made with the log-rank test.
Results: In total, 780 patients met inclusion criteria, and 109 patients received livers from donors older
than 70 years (range = 70–86). There were no differences in long-term patient (P = 0.67) or graft (P = 0.42)
survival between hepatitis C negative recipients of livers from older compared with younger donors. In
contrast, 7-year survival for HCV-positive recipients of older donor livers was less than half that of
HCV-negative recipients.
Discussion: Transplantation of livers from septua- and octogenarian donors can achieve excellent
long-term patient and graft survival for selected HCV-negative patients.
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Introduction
Liver transplantation is the standard of care for patients with
life-threatening acute and chronic liver disease, selected malig-
nancies and metabolic diseases. Unfortunately, there are simply
not enough deceased donor livers available for those in need
of liver transplantation.1 Numerous strategies to alleviate this
donor shortage have included the use of livers procured after
circulatory arrest, livers from donors with a higher risk of
disease transmission, livers with a higher risk of graft dys-
function or failure; split liver grafts; and living donor liver
transplantation.
Increasing donor age is known to adversely affect patient and
graft survival.2–7 Nevertheless, we wondered whether we could
achieve satisfactory patient and graft survival with the use of
livers from older donors. In 1998, we decided to expand our use
of older donor livers for selected patients: older patients, patients
with malignancies, patients perceived to be at a higher risk of
death than predicted by their model for end-stage liver disease
(MELD) scores and critically ill patients that might not survive
until a younger donor liver would become available for them.
We began using livers from septua- and octogenarian donors
and observed satisfactory short-term results.8 Encouraged by our
early success and reports by others,9,10 we increased our use of
older donor livers. The specific aim of this study was to deter-
mine whether the use of livers from septua- and octogenarian
decreased donors affected long-term patient and graft survival.
This work was presented at the 2012 Meeting of the Western Surgical Asso-
ciation, Colorado Springs, November 3–6 2012.
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Methods
We performed an Institutional Review Board approved retrospec-
tive analysis of all adult (age ≥ 18 years) patients that underwent
primary deceased donor liver transplantation at Mayo Clinic
Rochester between 1 July 1998 and 31 December 2010. Recipients
of liver allografts from living and domino amyloid donors, donor
organs procured after circulatory arrest, split and reduced-size
livers and recipients of simultaneous transplants (heart–liver and
kidney–liver) were not included in this study.
Deceased donor liver acceptance decisions were made after
review of donor clinical, biochemical, anatomical and histological
information. Liver biopsies were obtained on all donors at the time
of procurement and interpreted immediately for donors with sus-
picion of significant steatosis or liver disease. We used older donor
livers with mild (5%–33%) macrosteatosis, but we discarded older
donor livers with moderate (34%–66%) macrosteatosis and severe
(>66%) macrosteatosis. Pre-procurement percutaneous liver biop-
sies were obtained for some older donors in order to avoid costs of
non-productive procurement operations and travel.
Organ procurement for older donors was done in an identical
fashion to the procurement of livers from younger donors, with
an exception for donors with atherosclerosis precluding aortic
catheterization. All donor organs were procured with vascular
dissection and division of the common bile duct prior to perfu-
sion with University of Wisconsin solution (Via-Span, Barr
Laboratories Inc., Pomona, NY, USA or generic equivalent) or
Histidine-tryptophan-ketoglutarate, or Custodiol HTK (Essential
Pharmaceutical, Newton, PA, USA) through the distal aorta
and portal vein with 3 and 2 litres, respectively, or until the
hepatic vein effluent was clear. Several older donors with severe
aortic atherosclerosis or aortic dissection were flushed directly
through the celiac or common hepatic artery (along with portal
perfusion).
Recipient selection and deceased donor liver allocation were
done in complete accord with United Network for Organ Sharing
policy. Realizing that older donor livers might pose higher risks for
graft loss and death, we accepted older donor liver offers for
patients thought to be at increased risk for death or disease pro-
gression compared with other patients with similar MELD scores
(after February 2002) or waiting time (prior to February 2002).
Decisions to accept any given organ were made in the best interest
for each patient in order on the donor match run. We tried to
lessen the likelihood of prolonged cold ischaemia time for older
donor livers by avoiding patients with technically challenging
operations. We also occasionally began the transplant operation
prior to organ arrival at the transplant centre to minimize the cold
ischaemia time, especially for distant procurements. We made sure
that ABO compatible vessels were available for patients receiving
older donor livers that were likely to need arterial grafts – espe-
cially patients with cholangiocarcinoma for whom we routinely
use an infrarenal aortic arterial graft. Immunosuppression was per
our standard protocol (tacrolimus, mycophenolate mofetil, and
steroids with discontinuation of steroids and mycophenolate
mofetil by 3 months), regardless of donor age.
Patient and graft survival were calculated using the Kaplan–
Meier method, and survival comparisons were done with the log-
rank test. Results were stratified by donor age (older versus
younger than 70 years) and hepatitis C status. Comparisons of
categorical variables were performed using the Chi-square test,
and numerical variables were compared using Wilcoxon’s test.
Importantly, we analysed calculated MELD scores at the time of
transplantation, rather than appealed scores. For patients trans-
planted before February 2002 (beginning of MELD), we calcu-
lated MELD scores based on laboratory values at the time of
transplantation. P-values <0.05 were considered statistically
significant.
Results
Seven hundred and eighty primary adult liver transplants were
performed at Mayo Clinic Rochester between 1 July 1998 and 31
December 2010 and met criteria for inclusion in this study. One
hundred nine patients received allografts from deceased donors
≥ 70 years (median 76, range 70–86), including 28 patients that
received allografts from deceased donors ≥ 80 years. These
patients account for 109 of the 2563 (4.3%) patients that received
livers from donors older than 70 and 28 of the 365 (7.7%) patients
that received livers from donors older than 80 in the United States
during the period of this study (Scientific Registry of Transplant
Recipients, individual data request March 2013).
The remaining 671 patients received allografts from donors <70
years (median 43, range 6–69). Donor and transplant operative
data (Table 1) show comparable donor gender, anastomotic times
and cold ischaemia times between recipients of older versus
younger donors. The median serum creatinine for old donors was
1.2 versus 1.0 for young donors (P = 0.007). The median serum
glutamic oxaloacetic transaminase (GOT) was 34 for old donors
and 42 for younger donors (P = 0.04). The median serum
glutamate pyruvate transaminase (GPT) was 24 for the older
donor group and 33 for the younger donors (P < 0.0001). The
median total bilirubin was 0.7 for both groups (P = 0.73). There
were no differences in the degree of macrosteatosis between the
older and younger donor liver groups. Mild macrosteatosis was
present in 29% of the older donor livers and 24% of the younger
donor livers. Moderate macrosteatosis was present in only 1% of
the older donor livers (one graft) and 1.6% of the younger donor
group. Severe macrosteatosis was present in none of the older
donor livers and only 0.3% (two grafts) of the younger donor
group. Overall, macrosteatosis had an adverse effect on graft sur-
vival (P = 0.02). This adverse effect was no different between the
older donor and younger donor groups (P = 0.92). For livers
without any steatosis, graft survival for livers from older donors
was below that for the younger donor group, but the difference
was borderline (P = 0.053). Older donor recipients were signifi-
cantly older than younger donor recipients (median age 57 versus
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53 years, P = 0.0003), which was the intent of our policy for older
donor utilization. There were no statistical differences in recipient
gender, race, MELD scores, and malignancy as a primary diagnosis
between the older and younger donor recipients.
Fewer older donor recipients had hepatitis C compared with the
younger donor recipients (9% versus 23%, P = 0.0012) which was
the intent of our policy for older donor liver utilization. The most
common indications for liver transplantation among patients
receiving livers from septuagenarian and octogenarian donors
were hepatocellular carcinoma (n = 20), hilar cholangiocarcinoma
(n = 14), alcoholic cirrhosis (n = 14) and primary biliary cirrhosis
(n = 11).
The median post-transplant hospital stay was 9.7 days for recipi-
ents of old livers and 9.4 days for the younger donor group (P =
0.22). There were no differences in the rates of primary non-
function and early graft dysfunction leading to retransplantation
and/or patient death between recipients of younger compared with
older livers (2.75 for old donor liver recipients and 2.24 for younger
donor group, P = 0.73). There were no differences in arterial
complications (0.9% for recipients of old livers versus 3% for the
younger donor group,P = 0.34), portal vein complications (0% for
recipient of old livers versus 1.2% for the younger donor group,P =
0.61) or inferior vena cava complications (1.64 for old liver recipi-
ents versus 0.92 for the younger donor group,P > 0.99). There were
also no statistically significant differences in vascular complica-
tions between the two groups (1.8% for recipients of old livers
versus 5.5% for the younger donor group, P = 0.15). Interestingly,
recipients of livers from old donors had no biliary complications
compared with a 6.4% incidence of biliary complications for the
younger donor group (P = 0.002).
There were no statistically significant differences in patient (P =
0.89) or graft (P = 0.15) survival between recipients of septua- and
octogenarian donor livers (Fig. 1a,b). However, hepatitis C posi-
tive recipients had significantly worse patient (P = 0.03) and graft
(P = 0.006) survival for those that received livers from donors ≥ 70
years compared with those that received livers from donors < 70
years (Fig. 2a,b). They also had significantly worse patient (P =
0.009) and graft (P = 0.015) survival when compared with hepa-
titis C negative recipients that received livers from donors ≥ 70
(Fig. 2a,b). Indeed, patient and graft survival for hepatitis C posi-
tive patients at 7 years after transplantation were less than half of
the results observed in the other patient groups (Fig. 2c). Seven of
the 10 hepatitis C positive patients that received livers from sep-
tuagenarian donors developed graft failure resulting in death or
retransplantation, and five of these graft failures were as a result of
recurrent hepatitis C.
We did not observe significant differences in patient or graft
survival attributable to hepatitis C for recipients of livers from
donors < 70 years (Fig. 2a,b,c). We also did not observe significant
differences in patient or graft survival attributable to donor age
in non-hepatitis C patients (Fig. 2a,b,c) or in patients with
cholestatic liver disease (primary sclerosing cholangitis and
primary biliary cirrhosis).
Patients with HCV genotypes 2 and 3 had better patient sur-
vival (90% and 87.5% by 7 years) than patients with HCV geno-
types 1 and 4 (72.4% and 60%). Patients with HCV genotypes 2,
3 and 4 also had considerably better graft survival (90%, 79.5%
and 75%) than HCV genotype 1 recipients (66%). As a result of
the significant adverse effects of donor age ≥ 70 years on patient
and graft survival in hepatitis C positive recipients, we assessed the
effect of donor age for younger donors. The deleterious effects of
donor age on hepatitis C positive recipient patient and graft sur-
vival were significant for donors 60–69 years old within a few years
of transplantation and for donors 50−59 years old by 5 years after
transplantation (Fig. 3a,b).
Advanced donor age did not have any detrimental effects on
patient or graft survival for hepatitis C negative recipients. Patient
and graft survival for hepatitis C negative patients receiving livers
Table 1 Comparison of donor, transplant and recipient variables
Donors > 70 years Donors < 70 years P-value
Number of patients 109 671
Median donor age 76 (70–86) 43 (6–69) <0.0001
Donor gender, male (%) 56 (51%) 395 (59%) 0.14
Preservation solution, UW (%) 79 (75%) 495 (75%) 0.92
Median anastomosis time (min) 43 (23–87) 45 (27–72) 0.44
Median cold ischaemia time (min) 452 (188–532) 449 (144–880) 0.15
Median recipient age, years (range) 57 (21–71) 53 (18–73) 0.0003
Recipient gender, male (%) 62 (57%) 431 (64%) 0.14
Race, Caucasian (%) 100 (92%) 580 (88%) 0.25
MELD score, median (range) 19 (6–42) 18 (6–49) 0.54
Malignancy (%) 40 (37%) 251 (37%) 0.89
Hepatitis C (%) 10 (9%) 153 (23%) 0.0012
University of Wisconsin (UW) preservation solution (Via-Span, Barr Laboratories Inc., Pomona, NY, USA or generic equivalent). HTK (Essential
Pharmaceutical, Newton, PA, USA) was the other preservation solution.
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from septuagenarian donors (n = 71) and octogenarian donors
(n = 28) were similar to those for hepatitis C negative patients
receiving livers from younger donor age groups (Fig. 4a,b).
Discussion
Our experience accounted for 109 of the 2563 (4.3%) donors
older than 70 years and 28 of the 365 (7.7%) donors older than 80
years transplanted in the United States between 1 July 1998 and 31
December 2010 (Scientific Registry of Transplant Recipients, indi-
vidual data request March 2013). Our results show that use of
livers from septuagenarian and octogenarian deceased donors for
selected recipients did not have an adverse effect on long-term
patient or graft survival, provided that the recipients did not have
hepatitis C. Long-term patient and graft survival for hepatitis C
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(b)
Patient survival for liver transplant recipients of liver allografts from donors >
70 years old versus recipients of livers from donors < 70 years old (P = 0.89).
Graft survival for liver transplant recipients of liver allografts from donors > 70 
years old versus recipients of livers from donors < 70 years old (P = 0.15).
Figure 1 (a) Patient survival for liver transplant recipients of liver
allografts from donors > 70 years old versus recipients of livers from
donors < 70 years old (P = 0.89). (b) Graft survival for liver transplant
recipients of liver allografts from donors > 70 years old versus
recipients of livers from donors < 70 years old (P = 0.15)
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A
D
B
C
Number at risk        Time after transplantation (years)
A                            99        88       69       56      42       34        27      21       17       11        9
B                           518     459     410     363    318     278      235    186     141     110      93   
C                           153     130     119       99      90       84        74      62       51       35      27
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(a)
(b)
(c)
Donor age HCV N Patient / Graft survival (%)
1-Year 3-Year 5-Year 7-Year
> 70 No 99 95 / 88 90 / 80 82 / 73 77 / 65
< 70 No 518 93 / 89 87 / 84 83 / 80 78 / 75
> 70 Yes 10 80 / 70 70 / 50 50 / 40 38 / 30
< 70 Yes 153 86 / 84 82 / 78 79 / 75 75 / 72
0
Patient survival according to donor age and hepatitis C status of the recipient; P = 
0.01, for 4 group comparison; P = 0.24, for 3 group comparison (excluding 
hepatitis C positive recipients of liver allografts from deceased donors ≥ 70 years).
Graft survival according to donor age and hepatitis C status of the recipient; P = 
0.006 for 4 group comparison; P = 0.47 for 3 groups comparison (excluding hepatitis 
C positive  recipients who received livers from deceased donors ≥ 70 years).
Patient and graft survival according to HCV status and donor age 
Figure 2 (a) Patient survival according to donor age and hepatitis C
status of the recipient; P = 0.01, for four group comparison; P = 0.24,
for three group comparison (excluding hepatitis C positive recipients
of liver allografts from deceased donors ≥70 years). (b) Graft survival
according to donor age and hepatitis C status of the recipient; P =
0.006 for four group comparison; P = 0.47 for three groups com-
parison (excluding hepatitis C positive recipients who received livers
from deceased donors ≥70 years). (c) Patient and graft survival
according to HCV status and donor age
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positive recipients of older donor livers were less than half that for
hepatitis C negative patients and hepatitis positive C patients who
received younger donor livers.
Older donor age is well recognized as having an adverse effect
on outcome after liver transplantation. A multitude of previous
studies have shown an adverse effect on outcome after transplan-
tation attributable to advanced donor age,2–7,10–12 and the effect is
even more marked for recipients with hepatitis C.6,7,13,14 Our study
corroborates these findings.
Mutimer et al.4 evaluated the effect of donor age using a large
European database. Although the strongest negative impact of
donor age (over 60 years) was for hepatitis C recipients, older
donor age also adversely affected survival of alcoholic cirrhosis
patients without hepatitis C. Lake et al.15 evaluated 11 760 liver
transplants performed in the United States between 1995 and
2001. In this large registry study, donor age older than 60 years was
the strongest negative predictive factor for patients both with and
without hepatitis C. Interestingly, survival for hepatitis B patients
was not adversely affected by donor age older than 60 years. Few
studies have evaluated long-term outcomes of transplantation
specifically for livers from donors ≥ 70 years. Cuende et al.3 evalu-
ated 5150 liver transplants in a Spanish registry. Donor age ≥ 70
years was the most significant negative predictor of survival of the
52 donor variables included in the study. However, outcomes were
not stratified by recipient hepatitis C status. Similar results have
been reported by others.2,16 Reports on long-term outcomes with
the use of octogenarian donors are scarce and limited to small
series and case presentations.16–18 A multicentre Italian study
evaluated outcomes for 30 recipients of octogenarian donor livers.
Although follow-up was shorter than 5 years for most of the
cohort, 5 out of 13 hepatitis C positive patients who received
octogenarian livers died from aggressive hepatitis C recurrence.13
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Patient survival by donor age for hepatitis C positive recipients (P = 0.0008).
Graft survival by donor age for hepatitis C positive recipients (P < 0.0001).
Figure 3 (a) Patient survival by donor age for hepatitis C positive
recipients (P = 0.0008). (b) Graft survival by donor age for hepatitis C
positive recipients (P < 0.0001)
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Figure 4 (a) Patient survival by donor age for hepatitis C negative
recipients (P = 0.13). (b) Graft survival by donor age for hepatitis C
negative recipients (P = 0.24)
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Contrary to other studies, we did not observe a significant
adverse effect on survival associated with transplantation of livers
from donors ≥ 70 years in hepatitis C negative patients. Indeed,
the use of livers from septuagenarian and octogenarian donors did
not lead to an increased number of immediate post-transplant
complications. Similarly, the use of old livers did not impair long-
term patient or graft survival. We report 77% 7-year patient sur-
vival and 65% 7-year graft survival for hepatitis C negative
recipients of livers from septuagenarian and octogenarian donors.
Our results indicate that mild macrosteatosis does not have a
detrimental effect on older donor liver graft.
Several factors may account for our excellent results with older
donor livers, including careful recipient selection. We chose
patients that could tolerate temporary graft dysfunction and for
whom we did not expect difficult operations. We usually avoided
the use of older livers for critically ill patients. Recipients of livers
from old donors were older than recipients of young livers as that
was our intent. We tried to match older organs on to older recipi-
ents whenever possible. Although advanced recipient age is an
adverse prognostic factor for decreased patient survival, the 3-year
difference on median recipient age did not lead to inferior survival
for recipients of older livers. This observation should be viewed as
a protective bias to our favourable outcomes among recipients of
older livers. Livers from older donors may be more susceptible to
prolonged ischaemic times19–23 and prolonged cold ischaemia time
was avoided by our selection and timing efforts. We also
attempted to minimize organ cold ischaemia time by avoiding
technically complex operations and occasionally starting trans-
plant operations prior to arrival of the donor organ. The reason
why cold ischaemia times were similar between the older and
younger donor groups was that more of our older donor livers
were imported from other organ procurement organizations and
cold ischaemia times were prolonged as a result of transportation.
We acknowledge that other single centre, multiple centre and
registry studies show an adverse effect of older donor age on
patient and graft survival for patients without hepatitis C. Our
interpretation of our findings is that we were able to achieve
excellent patient and graft survival with older donor livers owing
to careful patient selection. We do not believe that it is appropriate
to use older donors indiscriminately as they become available for
patients awaiting transplantation. These livers should still be
avoided for patients high on the waiting list that are likely to
receive a better graft in the near future. Clinical judgement is
necessary to identify patients lower on the waiting list that are at a
greater risk of death and disease progression – patients that would
benefit from earlier transplantation with an older donor liver, in
spite of the potential for increased risks for graft dysfunction and
graft failure. Occasionally, it is necessary to use an older donor
liver for a critically ill patient that might not survive until a better
graft becomes available, but we do believe that outcome is less
than we would expect with a younger donor graft.
In contrast to our excellent results in patients without hepatitis
C, the outcome for hepatitis C recipients of older donor livers was
very poor. Ten patients with hepatitis C received livers from
donors ≥70 years, and patient and graft survival were less than half
that observed for other patients. There were a multitude of
reasons that these hepatitis C patients received older donor livers,
including critical illness, severe debility, high risk for death or
malignancy progression or a low likelihood of receiving a younger
donor liver. Based on our experience and the experiences reported
by others, we no longer use older donor livers for hepatitis C
patients. Not only is the outcome poor, but a hepatitis C negative
patient with a much better prognosis is deprived of an opportu-
nity to receive the older donor liver.
In conclusion, the use of deceased donor livers from septua-
genarian and octogenarian donors can provide excellent long-
term patient and graft survival for selected patients without
hepatitis C. These older donor livers should not be used for
patients with hepatitis C owing to a prohibitively high rate of
recurrent hepatitis C leading to graft loss and patient death. Our
results should provide guidance for other centres considering uti-
lization of livers from deceased septuagenarian and octogenarian
donors. Our results should also provide encouragement for organ
procurement organizations to be more enthusiastic about
working up and placing older donor livers as there are many
patients that would benefit from them.
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